1. A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk
- Author
-
Bernd Holleczek, Demetrius Albanes, Stephanie J. Weinstein, Yuen Y. E. Wong, Michael B. Cook, Alison M. Mondul, Konstantinos K. Tsilidis, Christopher A. Haiman, Jeannette M. Schenk, Kala Visvanathan, Loic Le Marchand, María José Sánchez, Pamela L. Lutsey, Freddie C. Hamdy, Harri Rissanen, Jenny L Donovan, Marc J. Gunter, David E. Neal, Shoichiro Tsugane, Bas Bueno-de-Mesquita, Tone Bjørge, Haakon E. Meyer, Rune Blomhoff, Mélanie Deschasaux, Mathilde Touvier, Pilar Galan, Lynne R. Wilkens, Tracy M. Layne, Johan Malm, Serge Hercberg, Timothy J. Key, Antonia Trichopoulou, Petra H.M. Peeters, Randi Elin Gislefoss, Amanda Black, Ruth C. Travis, Osvaldo P. Almeida, Domenico Palli, June M. Chan, Martin Almquist, Darryl W. Eyles, Elizabeth A. Williamson, Anja Olsen, Kathy J. Helzlsouer, Paul N. Appleby, Jonas Manjer, Hermann Brenner, Wen Yi Huang, Edward Giovannucci, Corinne E. Joshu, Regina G. Ziegler, Leon Flicker, Naomi E. Allen, Bu B. Yeap, Laura Perna, Giske Ursin, Meir J. Stampfer, Catherine M. Tangen, Richard M. Martin, Aurora Perez-Cornago, Norie Sawada, Paul Knekt, Ben Schöttker, Elizabeth A. Platz, Alicia K Heath, Dallas R. English, Nuffield Department of Population Health [Oxford], University of Oxford [Oxford], Division of Cancer Epidemiology and Genetics, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH)-National Institutes of Health [Bethesda] (NIH), Johns Hopkins Bloomberg School of Public Health [Baltimore], Johns Hopkins University (JHU), Division of Epidemiology and Community Health, University of Minnesota [Twin Cities], University of Minnesota System-University of Minnesota System, University of Michigan [Ann Arbor], University of Michigan System, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Julius Center for Health Sciences and Primary Care, University Medical Center [Utrecht], National Institute for Public Health and the Environment [Bilthoven] (RIVM), Hellenic Health Foundation, Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Department of Epidemiology and Biostatistics [Imperial College London], Imperial College London, Escuela Andaluza de Salud Publica, Instituto de Investigación Biosanitaria de Granada (Granada.ibs), Hospitales Universitarios de Granada/Universidad de Granada, CIBER de Epidemiología y Salud Pública (CIBERESP), Danish Cancer Society Research Center, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Saarland Cancer Registry, National Institute for Health and Welfare [Helsinki], The University of Western Australia (UWA), University of California [San Francisco] (UCSF), University of California, Harvard T.H. Chan School of Public Health, Cancer Registry of Norway, Institute of Population-based Cancer Research, University of Oslo (UiO), National Cancer Center, Cancer Epidemiology Centre & Cancer Council Victoria [Melbourne, Australia], University of Melbourne-Melbourne School for Population and Global Health, Queensland Brain Institute, University of Queensland [Brisbane], London School of Hygiene and Tropical Medicine (LSHTM), Skane University Hospital [Lund], University of Hawai'i [Honolulu] (UH), Keck School of Medicine [Los Angeles], University of Southern California (USC), Cancer Prevention Program, Fred Hutchinson Cancer Research Center [Seattle] (FHCRC), SWOG Southwest Oncology Group, University of Bristol [Bristol], Nuffield Department of Surgery, Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle (CRESS - U1153), Université Paris 13 (UP13)-Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Minnesota [Twin Cities] (UMN), Melbourne School for Population and Global Health-University of Melbourne, Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Paris 13 (UP13)-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), and Cancer Research UK [C8221/A19170]
- Subjects
Male ,0301 basic medicine ,Oncology ,1,25-dihydroxyvitamin D ,Aging ,Cancer Research ,MESH: Risk Assessment/methods ,MESH: Prostatic Neoplasms/etiology ,Disease ,Prostate cancer ,0302 clinical medicine ,Risk Factors ,MESH: Risk Factors ,Odds Ratio ,Prospective Studies ,Vitamin D ,Prospective cohort study ,ComputingMilieux_MISCELLANEOUS ,Cancer ,MESH: Aged ,MESH: Middle Aged ,Prostate Cancer ,Middle Aged ,25-hydroxyvitamin D ,MESH: Case-Control Studies ,3. Good health ,d metabolites ,Centre for Surgical Research ,030220 oncology & carcinogenesis ,ICEP ,pooled analysis ,Risk assessment ,Life Sciences & Biomedicine ,Urologic Diseases ,medicine.medical_specialty ,Clinical Trials and Supportive Activities ,Oncology and Carcinogenesis ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Risk Assessment ,Article ,vitamin D deficiency ,03 medical and health sciences ,MESH: Cross-Sectional Studies ,serum 25-hydroxyvitamin d ,Clinical Research ,subsequent development ,Internal medicine ,1,25-DIHYDROXYVITAMIN-D ,medicine ,Vitamin D and neurology ,Journal Article ,Humans ,Oncology & Carcinogenesis ,MESH: Vitamin D/blood ,Aged ,Nutrition ,Science & Technology ,MESH: Humans ,business.industry ,Prevention ,Case-control study ,Prostatic Neoplasms ,Odds ratio ,medicine.disease ,MESH: Male ,MESH: Odds Ratio ,MESH: Prospective Studies ,Cross-Sectional Studies ,030104 developmental biology ,1,25-dihydroxivatmin-d ,Case-Control Studies ,MESH: Vitamin D/analogs & derivatives ,MESH: Prostatic Neoplasms/blood ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,polymorphisms ,1112 Oncology And Carcinogenesis ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition - Abstract
Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH)2D for up to 13,462 men with incident prostate cancer and 20,261 control participants. ORs for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (multivariable-adjusted OR comparing highest vs. lowest study-specific fifth was 1.22; 95% confidence interval, 1.13–1.31; P trend < 0.001). However, this association varied by disease aggressiveness (Pheterogeneity = 0.014); higher circulating 25(OH)D was associated with a higher risk of nonaggressive disease (OR per 80 percentile increase = 1.24, 1.13–1.36) but not with aggressive disease (defined as stage 4, metastases, or prostate cancer death, 0.95, 0.78–1.15). 1,25(OH)2D concentration was not associated with risk for prostate cancer overall or by tumor characteristics. The absence of an association of vitamin D with aggressive disease does not support the hypothesis that vitamin D deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D concentration with a higher risk of nonaggressive prostate cancer may be influenced by detection bias. Significance: This international collaboration comprises the largest prospective study on blood vitamin D and prostate cancer risk and shows no association with aggressive disease but some evidence of a higher risk of nonaggressive disease.
- Published
- 2019